Intellectual property
Charles Lyon from Choate, Hall & Stewart chairs the firm’s IP group. Lyon’s focus is centred around due-diligence work and the prosecution side of patent portfolios. Lyon's clients are large and mid-size pharma companies including cross-border players.
Legal 500 Editorial commentary
- Profile
Accolades
Boston Elite
Mentions
Profile
Position
Dr. Charles Lyon, co-chair of Choate’s Intellectual Property Practice Group, provides strategic insight to investors and life sciences companies, both VC-backed and publicly-traded, to help them maximize the value of their investments in intellectual property by condensing complex data into actionable insights. Through hundreds of due diligence and intellectual property analysis projects, Charles has helped clients to understand, evaluate, and respond to IP issues that arise in the context of business transactions or during the research and development of new products and technologies. His insights have helped clients to identify “hot” areas in the life sciences landscape which have driven their strategic investment decisions – notably in the areas of immuno-oncology, gene therapy, gene editing, and cell therapy. He also routinely provides advice and opinions regarding freedom-to-operate and intellectual property landscape issues to assist with R&D decisions and in the context of pre-litigation disputes including Hatch-Waxman and Biosimilar litigation.
Charles has served investor clients including Bain Capital, Deerfield Management, 5AM Ventures, Third Rock Ventures, Venrock, Perceptive Advisors, and Broadview Ventures and life sciences companies including Takeda, Gilead, Biogen, GEMoaB, Editas Medicine, and Akouos.
Education
Boston College Law School
JD, 2006
MIT
Postdoctoral Associate, 2000
Biophysical Chemistry
University of Oxford
DPhil, 1999
Biophysical Chemistry
University of Cambridge
BA, 1996, First Class Honors
Natural Sciences
Content supplied by Choate, Hall & Stewart